The effects of ginger supplementation on common gastrointestinal symptoms in patients with relapsing-remitting multiple sclerosis: a double-blind randomized placebo-controlled trial

被引:0
|
作者
Foshati, Sahar [1 ]
Poursadeghfard, Maryam [2 ]
Heidari, Zahra [3 ]
Amani, Reza [4 ]
机构
[1] Shiraz Univ Med Sci, Nutr Res Ctr, Sch Nutr & Food Sci, Dept Clin Nutr, Shiraz, Iran
[2] Shiraz Univ Med Sci, Clin Neurol Res Ctr, Shiraz, Iran
[3] Isfahan Univ Med Sci, Sch Hlth, Dept Biostat & Epidemiol, Esfahan, Iran
[4] Isfahan Univ Med Sci, Sch Nutr & Food Sci, Dept Clin Nutr, Esfahan, Iran
关键词
Abdominal pain; Bloating; Constipation; Ginger; Multiple sclerosis; Nausea; ZINGIBER-OFFICINALE-ROSCOE; DIETARY SPICES; DIGESTIVE ENZYMES; ACTIVE PRINCIPLES; MOTILITY; MANAGEMENT; TRANSIT; OBESITY; FOOD;
D O I
10.1186/s12906-023-04227-x
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background Gastrointestinal (GI) symptoms affect more than 80% of individuals with relapsing-remitting multiple sclerosis (RRMS). Ginger is widely known for its GI relieving properties. Therefore, we investigated the effect of ginger supplementation on common GI symptoms in RRMS patients.Methods This study was a 12-week double-blind parallel randomized controlled trial with a 3-week run-in period. The intervention (n = 26) and control (n = 26) groups received 500 mg ginger and placebo (as corn) supplements 3 times a day along with main meals, respectively. At the beginning and end of the trial, the frequency and severity of constipation, dysphagia, abdominal pain, diarrhea, bloating, belching, flatulence, heartburn, anorexia, and nausea were assessed using the visual analogue scale ranging from 0 to 100 mm. Totally, 49 participants completed the study. However, data analysis was performed on all 52 participants based on the intention-to-treat principle.Results In comparison with placebo, ginger supplementation resulted in significant or near-significant reductions in the frequency (-23.63 +/- 5.36 vs. 14.81 +/- 2.78, P < 0.001) and severity (-24.15 +/- 5.10 vs. 11.39 +/- 3.23, P < 0.001) of constipation, the frequency (-12.41 +/- 3.75 vs. 3.75 +/- 1.82, P < 0.001) and severity (-13.43 +/- 4.91 vs. 6.88 +/- 2.69, P = 0.001) of nausea, the frequency (-9.31 +/- 4.44 vs. 1.56 +/- 4.05, P = 0.098) and severity (-11.57 +/- 5.09 vs. 3.97 +/- 3.99, P = 0.047) of bloating, and the severity of abdominal pain (-5.69 +/- 3.66 vs. 3.43 +/- 3.26, P = 0.069).Conclusion Ginger consumption can improve constipation, nausea, bloating, and abdominal pain in patients with RRMS.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] The effects of ginger supplementation on common gastrointestinal symptoms in patients with relapsing-remitting multiple sclerosis: a double-blind randomized placebo-controlled trial
    Sahar Foshati
    Maryam Poursadeghfard
    Zahra Heidari
    Reza Amani
    BMC Complementary Medicine and Therapies, 23
  • [2] A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis
    Romine, JS
    Sipe, JC
    Koziol, JA
    Zyroff, J
    Beutler, E
    PROCEEDINGS OF THE ASSOCIATION OF AMERICAN PHYSICIANS, 1999, 111 (01) : 35 - 44
  • [3] Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial
    Rahimlou, Mehran
    Nematollahi, Shima
    Husain, Durdana
    Banaei-Jahromi, Nasrin
    Majdinasab, Nastaran
    Hosseini, Seyed Ahmad
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [4] A placebo-controlled, randomized, double-blind, MRI trial of antiherpes therapy in patients with relapsing-remitting multiple sclerosis (RRMS)
    Jakobsen, J
    Bech, E
    Gadeberg, P
    Hansen, HJ
    Christensen, T
    Haahr, S
    Hollsberg, P
    Lycke, J
    Malmestrom, C
    Ekholm, S
    Bergstrom, T
    Svennerholm, B
    Andersen, O
    NEUROLOGY, 2001, 56 (08) : A74 - A74
  • [5] Acyclovir treatment of relapsing-remitting multiple sclerosis - A randomized, placebo-controlled, double-blind study
    Lycke, J
    Svennerholm, B
    Hjelmquist, E
    Frisen, L
    Badr, G
    Andersson, M
    Vahlne, A
    Andersen, O
    JOURNAL OF NEUROLOGY, 1996, 243 (03) : 214 - 224
  • [6] Efficacy and Safety of Tabalumab in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
    Silk, Maria
    Nantz, Eric
    NEUROLOGY, 2018, 90
  • [7] Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial (vol 16, 901846, 2022)
    Rahimlou, Mehran
    Nematollahi, Shima
    Husain, Durdana
    Banaei-Jahromi, Nasrin
    Majdinasab, Nastaran
    Hosseini, Seyed Ahmad
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [8] A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis
    Louapre, C.
    Rosenzwajg, M.
    Golse, M.
    Roux, A.
    Pitoiset, F.
    Adda, L.
    Tchitchek, N.
    Papeix, C.
    Maillart, E.
    Ungureanu, A.
    Charbonnier-Beaupel, F.
    Galanaud, D.
    Corvol, J. C.
    Vicaut, E.
    Lubetzki, C.
    Klatzmann, D.
    JOURNAL OF NEUROLOGY, 2023, 270 (09) : 4403 - 4414
  • [9] A double-blind, placebo-controlled, multicentre study to evaluate dirucotide in relapsing-remitting multiple sclerosis
    Selmaj, K.
    Verco, T.
    Ossanna, M.
    Nilsson, M.
    Ferenczi, L.
    Chappell, A.
    Arfors, L.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S235 - S235
  • [10] Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis A Randomized, Placebo-Controlled Trial
    Bellmann-Strobl, Judith
    Paul, Friedemann
    Wuerfel, Jens
    Doerr, Jan
    Infante-Duarte, Carmen
    Heidrich, Elmira
    Koertgen, Benedict
    Brandt, Alexander
    Pfuller, Caspar
    Radbruch, Helena
    Rust, Rebekka
    Siffrin, Volker
    Aktas, Orhan
    Heesen, Christoph
    Faiss, Juergen
    Hoffmann, Frank
    Lorenz, Mario
    Zimmermann, Benno
    Groppa, Sergiu
    Wernecke, Klaus-Dieter
    Zipp, Frauke
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (03):